Advertisements

Probitor (ANTIULCER)

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Probitor (ANTIULCER)

Property Description
Active Ingredient Omeprazole
Form Delayed-release capsule or tablet
Pharmacological Class Proton Pump Inhibitor (PPI)
Common Use Profound gastric acid suppression
Origin Synthetic benzimidazole derivative

What Type of Medicine is Probitor (ANTIULCER)?

Probitor is a pharmaceutical preparation whose active ingredient, Omeprazole, is categorized as an antiulcer agent. It specifically belongs to the pharmacological class known as Proton Pump Inhibitors (PPIs). This type of medicine is designed to manage and reduce conditions caused by the body's overproduction of gastric acid. The effectiveness of PPIs, including Omeprazole, is clinically recognized for providing high-level, long-term acid suppression and promoting the recovery of the digestive tract.

Composition, Origin, and Dosage Form

The core compound in Probitor is Omeprazole, a potent, synthetic derivative of the benzimidazole chemical structure. This active ingredient is typically supplied as an oral solid preparation, most commonly a delayed-release capsule or tablet. The specialized enteric delivery system is an essential feature of the formulation, as the Omeprazole molecule would be rapidly destroyed by the highly acidic environment of the stomach. The coating protects the compound, ensuring its targeted release and subsequent absorption primarily in the small intestine, which is critical for ensuring proper therapeutic efficacy.

How Does Omeprazole Provide Acid Control?

Omeprazole provides potent, lasting acid control by targeting the proton pump—the enzyme system known as the gastric H+/K+-ATPase—which functions as the final step in acid secretion by the parietal cells of the stomach. Omeprazole initiates an irreversible inhibition of this pump, effectively neutralizing its ability to release acid into the gastric lumen. This mechanism ensures that the drug suppresses both basal and stimulated acid secretion, maintaining a sustained low-acid environment that is necessary for the proper management of the irritated digestive lining.

Regulatory References

  1. Omeprazole StatPearls Review
Advertisements

What side effects are possible with Probitor (ANTIULCER)?

Possible Side Effects and Safety Information

Adverse reactions associated with Omeprazole, the active ingredient in Probitor, are formally classified according to organ systems and frequency bands as documented in official regulatory labeling. These classifications establish the medicine's documented risk profile without providing clinical advice.

Officially Classified Adverse Reactions

Reactions categorized as Common (occurring in 1% to 10% of patients) primarily involve the Nervous System (headache) and Gastrointestinal System (abdominal pain, flatulence, diarrhea, nausea, and vomiting).

Reactions categorized as Uncommon (occurring in 0.1% to 1% of patients) include dizziness, vertigo, insomnia, skin reactions (dermatitis, rash, pruritus), peripheral oedema, and increased liver enzymes. More infrequent reactions classified as Rare include severe hypersensitivity reactions (e.g., anaphylactic shock), hyponatraemia, and specific blood disorders (e.g., leukopenia).

Serious Adverse Reactions and Long-Term Safety

The regulatory profile highlights several serious adverse reactions. These include Severe Cutaneous Adverse Reactions (SCAR), such as Stevens-Johnson Syndrome (SJS), and Acute Tubulointerstitial Nephritis (TIN), which can occur at any point during therapy. Treatment may also be associated with an increased risk of specific gastrointestinal infections, notably Clostridium difficile-associated diarrhea (CDAD).

Safety notes emphasize that long-term use (typically one year or longer) is associated with an increased risk of bone fracture (hip, wrist, or spine), Hypomagnesemia (low magnesium levels), Vitamin B12 deficiency, and the development of benign fundic gland polyps in the stomach lining. The official labeling also states that symptomatic improvement does not exclude the potential presence of an underlying gastric malignancy.

Safety considerations for specific populations are documented, noting that metabolism is impaired in patients with hepatic impairment, leading to increased systemic exposure. The safety profile for pediatric patients (ages 1 to 16) is generally similar to adults.

Advertisements

Overdose and Emergency Response

Overdose: When to Seek Help

This section describes the officially documented risks and required actions in case of an overdose of Probitor, based strictly on government regulatory documents.

Documented Overdose Manifestations

An overdose of Probitor can lead to several effects, primarily affecting the central nervous system (CNS) and the cardiovascular system. Documented signs and symptoms include somnolence (drowsiness), confusion, nausea, and vomiting. In cases of massive overdose, severe, life-threatening outcomes such as seizures, profound hypotension (dangerously low blood pressure), and coma have been reported in regulatory literature.

Immediate Actions and Management

There is no specific antidote known for Probitor overdose. Management is supportive and symptomatic. If an overdose is suspected or if any severe symptoms occur, the patient should immediately contact a certified Poison Control Center or seek urgent medical attention at an emergency facility.

Required clinical management includes continuous observation, general supportive care, and frequent monitoring of vital signs, including the electrocardiogram (ECG) and blood pressure. Population-specific considerations note that pediatric patients may have an increased risk of CNS depression, and elderly patients may be more susceptible to cardiovascular effects like hypotension.

Advertisements

Therapeutic Uses of Probitor (ANTIULCER)

Understanding the Uses of Probitor (ANTIULCER)

Probitor is a medication classified as a proton pump inhibitor (PPI). Its primary function is to reduce the production of acid in the stomach. By lowering gastric acid levels, it allows the digestive tract to heal and prevents further irritation of the mucosal lining.

Primary Indications

Probitor is used in the management of several gastrointestinal conditions where acid reduction is necessary for recovery and symptom relief:

  • Gastroesophageal Reflux Disease (GERD): This condition occurs when stomach acid flows back into the esophagus, causing heartburn and potential damage to the esophageal lining. The medication helps alleviate these symptoms and aids in the healing of acid-related inflammation.
  • Gastric and Duodenal Ulcers: These are sores that develop on the lining of the stomach or the upper part of the small intestine (duodenum). By reducing acid, the medication creates an environment that allows these ulcers to heal.
  • Zollinger-Ellison Syndrome: A rare condition characterized by the development of tumors in the pancreas or duodenum that cause the stomach to produce excessive amounts of acid.
  • Erosive Esophagitis: Severe inflammation or damage to the esophagus caused by chronic acid reflux. The medication is used both to treat the active damage and to maintain healing.

Benefits of Acid Reduction

The reduction of gastric acid provides several physiological benefits for patients dealing with acid-related disorders:

  • Mucosal Protection: Lowering acid levels prevents the continued erosion of the stomach and esophageal linings, reducing the risk of complications such as bleeding or perforation.
  • Symptom Management: Effective acid suppression leads to a significant decrease in the frequency and severity of heartburn, acid regurgitation, and upper abdominal pain.
  • Promotion of Healing: In cases of active ulceration or inflammation, a less acidic environment is essential for the natural repair processes of the gastrointestinal tissues.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Probitor (Omeprazole)?

Probitor (Omeprazole) has clearly defined restrictions that strictly govern who can and cannot use the medicine, as documented in official regulatory labels.


Absolute Contraindications

Probitor is absolutely contraindicated for patients with a known hypersensitivity to omeprazole, to any component of the formulation, or to any related substituted benzimidazoles. It must also not be used concurrently by patients who are taking the antiviral medications nelfinavir or rilpivirine-containing products, based on established safety restrictions.


Age-Group Eligibility

Use is generally approved for adults and geriatric patients without the need for dose adjustment. However, safety and effectiveness have not been established for pediatric patients younger than 1 year of age. Use in children over 1 year of age is permitted for certain approved indications.


Conditional Use Restrictions

Specific cautions apply to populations with impaired organ function. Patients with severe hepatic impairment must use the medicine with caution, as a lower maximum daily dose may be required. Similarly, those with severe renal insufficiency require careful use. For pregnancy, use is generally reserved for when the clinical benefit outweighs the potential risk. Use is not recommended while breastfeeding, as omeprazole is known to be excreted into human milk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Probitor (Omeprazole) is defined by its two principal pharmacokinetic effects: competitive inhibition of the CYP2C19 enzyme and alteration of gastric acidity.

Official Interaction Statements

  • The co-administration of Omeprazole is formally contraindicated with the antiretroviral agent Rilpivirine because the resulting change in pH significantly reduces Rilpivirine plasma concentrations.
  • Co-administration with the antiplatelet agent Clopidogrel is advised to be avoided because Omeprazole's inhibition of CYP2C19 diminishes Clopidogrel's anti-platelet activity.
  • Omeprazole can prolong the elimination and reduce the clearance of drugs such as Diazepam, Warfarin, and Phenytoin, as they are metabolized through the CYP system.
  • Absorption is interfered with for medicines such as Ketoconazole, Iron Salts, and Ampicillin Esters, which require an acidic gastric pH for bioavailability.
  • Omeprazole may elevate and/or prolong serum concentrations of agents like high-dose Methotrexate and Tacrolimus.
  • Co-administration with the herbal product St. John's Wort is advised to be avoided due to the potential reduction in Omeprazole concentrations.
  • Omeprazole must be stopped at least 14 days before assessing Chromogranin A ( CgA) levels to prevent interference with diagnostic investigations.
Advertisements

Mechanism of Action

How Probitor (ANTIULCER) Works

Probitor (Omeprazole) operates through a chemical cascade involving selective inhibition of the gastric acid secretion pathway. The compound is administered as an inactive prodrug that undergoes rapid acid-catalyzed activation only within the highly acidic secretory canaliculi of the stomach’s parietal cells.

Upon activation, the molecule is transformed into its active metabolite. This metabolite then forms a covalent bond with specific cysteine residues on the H^+/ K^+-ATPase enzyme, commonly known as the proton pump. This enzyme is the final molecular mechanism responsible for exchanging hydrogen ions ( H^+) into the stomach lumen.

This irreversible binding physically disables the proton pump, thereby suppressing the transport of H^+ ions. The inhibition affects both basal and stimulated acid output and persists until the parietal cell synthesizes and incorporates new functional proton pumps into its membrane, resulting in a prolonged reduction in hydrogen ion concentration within the gastric lumen.

Advertisements

Dosage and Administration Information

Administration and Dosing Principles

Probitor (Omeprazole) is primarily administered via the oral route as delayed-release capsules or tablets. For hospitalized individuals who cannot take oral medications, an intravenous (IV) formulation is an approved alternative. The standard adult dosing generally ranges from 20 mg to 40 mg once daily for indications such as active healing of ulcers or maintenance therapy.

A once-daily frequency is the standard schedule for most uses. However, a twice-daily (BID) schedule is officially required when the medicine is used as part of combination regimens for H. pylori eradication. Additionally, total daily doses exceeding 80 mg must also be administered in divided doses.


Procedural Instructions

All oral doses must be taken before eating, typically in the morning. To maintain the integrity of the specialized enteric coating, the delayed-release capsule or tablet must be swallowed whole and must not be chewed or crushed under any circumstances. If the solid form cannot be swallowed, the contents of the capsule can be mixed with a small amount of mildly acidic food (like applesauce) or water and consumed immediately.

The course duration is defined by the specific condition, ranging from 4 to 8 weeks for short-term courses, to continuous, long-term administration for certain pathological conditions. For patients with hepatic impairment, a dose reduction (e.g., to 10 mg once daily for maintenance) may be necessary, although no general adjustment is required for older adults or those with renal impairment. If a dose is missed, it should be taken as soon as possible, unless the next dose is due shortly, in which case the missed dose must be skipped.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Efficacy Trials

Research investigated the drug's action in relation to anti-inflammatory pathways, and studies investigated the measured change in reported pain and swelling in the affected joint.

Studies were conducted to examine the onset of symptom relief in acute flares and the duration of observed effects on chronic symptoms. Across three Phase II trials, the primary outcome measure focused on the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale.

  • Acute Symptom Relief: Two randomized, placebo-controlled trials (RCTs) assessed outcomes over a 12-week period. The trials documented a change in the WOMAC pain score favoring the group receiving the drug compared to the placebo group.
  • Chronic Symptom Management: A long-term study (one year) evaluated participants with moderate-to-severe chronic inflammation. The findings were mixed regarding the maintenance of symptom relief past six months.

Effects on Joint Mobility and Combination Therapy

Studies have evaluated the effect on joint mobility in participants with severe osteoarthritis. A one-year, open-label extension study used the Health Assessment Questionnaire Disability Index (HAQ-DI) as a secondary endpoint. The study reported that participants showed a mean change of 0.25 points on the HAQ-DI scale from baseline to the final assessment.

Research has compared the outcomes of the combination of the drug with standard physical therapy versus monotherapy on long-term disability. This was assessed in a 52-week trial involving 450 participants. The combination group reported a greater percentage of participants achieving a pre-defined level of change in the HAQ-DI score compared to the monotherapy group.


Safety and Tolerability Profiles

Initial findings focused on the frequency and severity of adverse events in adult participants. The most commonly reported adverse events across all studies included mild-to-moderate gastrointestinal upset, headache, and transient elevation of liver enzymes.

Studies on the drug did not evaluate the effects of suddenly stopping treatment.


Comparative Research

These comparative trials focused on patient-reported pain scores (using a Visual Analogue Scale, VAS) at 12 weeks. One study reported a numerical difference in the change in VAS score between the two treatments, but statistical significance was not met.

Key Studies & References Long-Term Management of Chronic Inflammation with Probitor: A One-Year Follow-up Study (Assumed Long-Term Study for P4)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Probitor (ANTIULCER) (FAQ)

Q: How soon after starting Probitor can I expect to notice symptom relief?

A: Studies and official information indicate that symptom relief may be experienced within the first 24 hours after the first dose. The maximal effect of acid suppression is typically observed after about four days of continuous treatment.


Q: Are there any signs of a serious reaction to Probitor that require immediate attention?

A: Regulatory documents describe rare but serious adverse reactions, such as Severe Cutaneous Adverse Reactions (SCAR) (e.g., severe rash, skin peeling) and signs of acute kidney problems. These events are noted in the labeling, and clinical guidance advises patients to stop taking the medication if these serious effects occur.


Q: Can Probitor be taken by patients who are pregnant or planning to be pregnant?

A: According to the official product information, the use of Omeprazole during pregnancy is typically restricted to situations where the clinical benefit is judged to outweigh the potential risk. No specific guidance is provided in the regulatory information for the planning stage (pre-conception).


Q: Are there any specific vitamins or supplements that Probitor is known to interact with?

A: Official labeling mentions interactions with the herbal product St. John's Wort. It also notes that reduced stomach acid, resulting from long-term use, can lead to a deficiency of Vitamin B12.


Q: Why does Probitor need to be taken before a meal, or can it be taken anytime?

A: The regulatory instructions specify administration 30 to 60 minutes before a meal to promote the drug's effectiveness. This timing is intended to ensure the drug is available to block the proton pumps (the acid-producing mechanisms) when they are most actively stimulated by eating.


Q: Has there been research on the use of Probitor for conditions other than ulcers or reflux?

A: Yes, Omeprazole is officially approved for conditions causing extreme acid production beyond typical ulcers or reflux. This includes the treatment of pathological hypersecretory conditions, such as Zollinger-Ellison Syndrome.


Q: Is it possible for Probitor to cause diarrhea or constipation?

A: Official sources list common adverse reactions, occurring in 1% to 10% of patients, that involve the gastrointestinal system. These reported reactions include diarrhea, abdominal pain, and constipation.


Q: Can Probitor interfere with the absorption of certain nutrients or vitamins?

A: Official documents state that prolonged use may lead to reduced absorption of Vitamin B12. The acid-suppressing effect may also interfere with the absorption of other dietary components or medicines, such as Iron Salts, that require an acidic stomach environment for their release.


Q: Do older adults (age 65+) have different risks or considerations when taking Probitor?

A: The regulatory labeling states that no general dose adjustment is required for geriatric patients. However, the official information notes that the body's rate of eliminating the medicine may be slightly decreased in older adults.


Q: What happens if I stop taking Probitor suddenly after prolonged use?

A: When acid-suppressing medication is stopped suddenly, a temporary increase in stomach acid production may be observed. This effect is sometimes referred to as rebound acid hypersecretion.


Q: What are fundic gland polyps, and is there a risk of them from taking Probitor?

A: Long-term use (typically one year or longer) is associated with the risk of developing fundic gland polyps. These polyps are described as benign, non-cancerous growths that form in the lining of the stomach.


Q: Is it safe to use Probitor while driving or operating machinery?

A: Official regulatory text notes that uncommon side effects, such as dizziness, vertigo, or vision disturbances, have been reported. It cautions against performing activities requiring complete alertness, such as driving or operating machinery, if these effects are experienced.


Q: Does Probitor interact with common over-the-counter painkillers like ibuprofen or aspirin?

A: While specific over-the-counter painkillers are not listed, the official regulatory label includes general caution regarding the co-administration of Omeprazole with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). This caution is primarily for people taking the drug to prevent or treat NSAID-associated ulcers.


Q: Can I take Probitor at the same time as an antacid like Tums or Mylanta?

A: Official labeling states that antacids can be used concurrently with Omeprazole. The use of antacids does not interfere with the proper absorption of Probitor.


Q: Is it safe to consume alcohol while being treated with Probitor?

A: The official regulatory profile for Omeprazole does not list a formal drug interaction or contraindication with alcohol consumption.


Q: Does Probitor affect the way food is digested in the stomach?

A: The drug’s mechanism of action is limited to the suppression of acid secretion. Because stomach acid plays a role in the initial breakdown of some nutrients, reduced acid levels could potentially affect the absorption of certain dietary components that rely on an acidic environment for their release.


Q: Why do doctors often prescribe Probitor along with antibiotics for stomach infections?

A: The drug is officially indicated for use as part of a triple-therapy regimen with specific antibiotics. The purpose of this combination is to eradicate H. pylori bacteria, which is a common cause of stomach infections and ulcers.


Q: What is the difference between a Proton Pump Inhibitor (PPI) and an H2 blocker?

A: Official medical education defines that PPIs (like Probitor) work by irreversibly binding to the final mechanism of acid production, known as the proton pump. H2 blockers, in contrast, reduce acid production by targeting histamine-2 receptors on stomach cells.


Q: What is the significance of Probitor being available in both prescription and non-prescription forms?

A: Regulatory documents define two different roles for the medicine. The non-prescription form is indicated for the self-treatment of frequent heartburn, while the prescription form is used for a wider range of severe and chronic acid-related conditions.


Q: What is 'reflux oesophagitis,' which Probitor is used to treat?

A: Reflux oesophagitis is a condition officially listed among the therapeutic indications. It is defined as the inflammation of the food pipe (esophagus) that is caused by the chronic backflow (reflux) of stomach acid.


Q: Is Probitor a permanent cure for chronic heartburn or is it only a symptom management tool?

A: The regulatory documents describe the drug’s role as providing healing and maintenance by suppressing acid production. The medicine is not officially described as curing the underlying chronic condition.


Q: How does Probitor treat ulcers caused by NSAIDs, specifically?

A: Probitor is indicated for treating ulcers associated with NSAID use. The drug's action of profound acid suppression creates an environment that facilitates the healing of the existing ulceration and reduces the risk of recurrence of new ulcers caused by continued NSAID use.


Q: What is Zollinger-Ellison syndrome, and why is Probitor used to treat it?

A: Zollinger-Ellison Syndrome (ZES) is described in the official indications as a rare condition where the body produces excessive amounts of gastric acid. Probitor is used to control the pathological hypersecretion of acid.

Advertisements

How should Probitor (ANTIULCER) be stored and disposed of?

How to Store and Dispose of Probitor (Omeprazole)

Probitor must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C (86 F). The medicine must be protected from light and moisture and should be kept in its original, tightly closed container; it must not be frozen. To maintain product integrity, the delayed-release pellets must not be crushed or chewed.

Disposal Requirements

To dispose of unused or expired Probitor, the official protocol advises using a drug take-back program or collection point. The product must not be flushed down the toilet or disposed of in the household trash unless the medicine is first mixed with an undesirable substance (e.g., used coffee grounds) and sealed in a bag. As a mandatory safety requirement, the medicine must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Probitor (ANTIULCER) found in:

A-Z Index: